Tuberculosis and Bladder Cancer

Описание: We discuss how a live attenuated version of tuberculosis called Bacillus Calmette-Guerin (BCG) can be used to help delay the progression of non-muscle invasive bladder cancer. BCG is thought to cause an inflammatory reaction in the bladder that recruits immune cells to get rid of leftover bladder cancer cells. While BCG is an effective treatment, it can also be irritating and painful for some patients, and there is currently a shortage of BCG. Here are some of the FDA approved alternatives to BCG :
1. ANKTIVA® (nogapendekin alfa inbakicept-pmln): An immunotherapy indicated for BCG-unresponsive NMIBC with carcinoma in situ (CIS), with or without papillary tumors. It is administered in combination with Bacillus Calmette-Guérin (BCG).
2. ZUSDURI™ (mitomycin) for intravesical solution: A chemotherapy agent for the treatment of recurrent low-grade, intermediate-risk NMIBC.
3. INLEXZO™ (gemcitabine intravesical system): A slow-release chemotherapy system for adult patients with BCG-unresponsive NMIBC with CIS, with or without papillary tumors.
4. KEYTRUDA - intravesical pembrolizumab

🏷️ BCG, tuberculosis, bladder cancer, American urological association, captions app, muscle-invasive, doctor, urology, physician

#bladdercancer #tuberculosis #urologyimmunotherapy #chemotherapy #immunotherapy #urology #residency #urologylife #premed #medstudent #doctor #womeninsurgery #residencylife #surgeon #bcg #bcgimmunotherapy #uronurse